

American Journal of Kidney Diseases  
Volume 49, Issue 1, Pages 135-142 (January 2007)

**“Results: DaVita’s percentage of monthly claims for patients with hemoglobin levels of 13 g/dl or greater ( $\exists$  130 g/L; 16.7%) and mean monthly rHuEPO dose (54,299 units) were highest....”**

<http://www.ajkd.org/article/PIIS0272638606015204/abstract>

//